Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 17/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070834 | 0.93 | CYP3A4 (0.56) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL3323529 | 0.88 | MAOA (0.69) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL3328646 | 0.88 | MAOA (0.72) | CYP3A4CYP2D6MAOAMAOBCYP2C9 | |
| SCHEMBL5956242 | 0.86 | MAOA (0.71) | CYP3A4CYP2D6MAOACYP2C9 | |
| SCHEMBL5956238 | 0.86 | MAOA (0.71) | CYP3A4CYP2D6MAOACYP2C9 | |
| SCHEMBL5930549 | 0.86 | MAOA (0.70) | CYP3A4CYP2D6MAOACYP2C9 | |
| SCHEMBL4699825 | 0.86 | MAOA (0.72) | CYP3A4CYP2D6MAOACYP2C9 | |
| SCHEMBL14559455 | 0.86 | MAOA (0.72) | CYP3A4CYP2D6MAOACYP2C9 | |
| SCHEMBL3323213 | 0.86 | MAOA (0.72) | CYP3A4CYP2D6MAOACYP2C9 | |
| SCHEMBL3325871 | 0.85 | CYP3A4 (0.62) | CYP3A4CYP2D6MAOAMAOBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105484-A1 | PROCESS FOR THE PREPARATION OF ARYL SUBSTITUTED OXAZOLIDINONES AS INTERMEDIATES FOR ANTIBACTERIAL AGENTS | ASTRAZENECA (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | NR0B2, NR0B1, HRH2 | CYP3A4 372/4885CYP2D6 114/4885MAOA 293/4885 |
| US-20090105484-A1 | PROCESS FOR THE PREPARATION OF ARYL SUBSTITUTED OXAZOLIDINONES AS INTERMEDIATES FOR ANTIBACTERIAL AGENTS | OXA1L, INTS6, CYP2F1 | CYP3A4 13/4885CYP2D6 37/4885MAOA 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.